Eli Lilly and Company (LLY)
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition costs. Even though oncology, the segment in which the acquisition was made, has been lackluster in Q1 2025, it shows promise when seen over the longer term. In any case, there's a case for the company to diversify at a time when it's facing downward pressure on prices from policy, compounders, and fakes.
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion
Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio.
Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%.
A report said the two pharmaceutical companies are in advance talks.
Eli Lilly lining up $1.3bn swoop for cholesterol specialist Verve
Eli Lilly and Co (NYSE:LLY) is in advanced discussions to acquire Verve Therapeutics in a deal worth up to $1.3 billion, according to the Financial Times. The proposed terms include a nearly $1 billion upfront payment, with an additional $300 million contingent on clinical milestones.
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, the Financial Times reported on Monday, citing people familiar with the matter.
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Eli Lilly (LLY) stood at $807.58, denoting a -1.44% move from the preceding trading day.
Want a $1 Million Retirement Portfolio? Invest $100,000 in These 3 Stocks and Wait 10 Years
Key Points in This Article: Growing a $100,000 investment into a $1 million retirement portfolio in 10 years requires a 25.9% CAGR from high-growth stocks with solid financials.
Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay Journey Program In a clinical trial, adults with obesity or overweight and a weight-related medical condition taking Zepbound 15 mg lost 48 lbs (~21% weight loss) and approximately 1 in 3 on Zepbound 15 mg lost over 58 lbs (25% weight loss) INDIANAPOLIS , June 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month through LillyDirect's Self Pay Pharmacy Solutions and the Zepbound Self Pay Journey Program.1 Health care providers can begin prescribing the 12.5 mg and 15 mg vials on July 7, and shipments to patients will begin in early August. With the addition of these doses, every strength of Zepbound vial will be available for $499/month or less ($349 for the 2.5 mg starter dose) to any eligible adult with obesity and a valid prescription, regardless of insurance.
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
Eli Lilly and Company LLY has reached a significant support level, making it an attractive option for investors from a technical standpoint. Earlier this week, the stock broke through its 50-day simple moving average (SMA), indicating a potential short-term bullish trend.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (June 2025)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health
Research will leverage world's first AI-enabled screening platform for mapping the therapeutic potential of secreted signaling proteins, developed by Juvena Collaboration aims to accelerate the discovery of treatments that help individuals maintain and even improve their muscle mass and function REDWOOD CITY, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and metabolic diseases, today announced it has entered a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) to discover, develop, and commercialize drug candidates that improve muscle health and body composition.
